Impact of bariatric surgery on the absorption of lercanidipine
Official title: Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine
Run by Norwegian University of Science and Technology · NCT03497156 · Data updated 2026-11-12
This study looks at how bariatric surgery affects how well the medication lercanidipine is absorbed in patients who have had weight loss surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Norwegian University of Science and Technology Academic / other |
| Locations | 1 site (Trondheim) |
| Status | Recruiting |
| Started | November 2, 2016 |
| Main results expected | October 2026 |
| Study ends | October 2026 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT03497156 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Norwegian citizens preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway.
✕Probably not a fit
Patients who have previously undergone resections in the gastrointestinal tract may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates how bariatric surgery, specifically gastric bypass and sleeve gastrectomy, affects the pharmacokinetics of the medication lercanidipine in patients. It aims to understand changes in gastric pH, gastric emptying time, and gastrointestinal transit time that may influence the biological availability of this drug. By examining these factors, the study seeks to provide insights into how surgical interventions for obesity can alter medication absorption and effectiveness.
Why it matters
Potential benefit: If successful, this study could lead to improved medication management for patients undergoing bariatric surgery.
How similar studies have gone: While there is limited research on this specific topic, studies examining the pharmacokinetics of medications post-bariatric surgery have shown varying results, indicating a need for further investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract
Where it's running
-
St. Olavs University Hospital
Trondheim, Norway Recruiting
Study contacts
- Principal investigator: Magnus Strømmen, MSc — St. Olavs Hospital
- Study coordinator: Magnus Strømmen, MSc
- Email: magnus.strommen@stolav.no
- Phone: 0047 72829970
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Glycemic variability after SASI versus Roux-en-Y gastric bypass
This trial tests whether SASI or Roux-en-Y gastric bypass leads to different glucose fluctuations in adults with severe obesity using continuous glucose monitoring.
-
Postoperative nausea, vomiting and pain after bariatric surgery in Sweden
This study looks at how often people have nausea, vomiting, and pain after bariatric surgery in Sweden and whether anesthesia type or regional blocks affect those outcomes.
-
Low-impact laparoscopy for sleeve gastrectomy in adults with obesity
This will see if low-pressure, small-incision laparoscopy reduces post-surgery pain and improves breathing after sleeve gastrectomy in adults with obesity.
-
Tranexamic acid to reduce bleeding in sleeve gastrectomy and mini gastric bypass
This trial will test whether giving tranexamic acid before laparoscopic sleeve gastrectomy or mini gastric bypass reduces bleeding in adults with morbid obesity.
-
Predicting Quality of Life After Bariatric Surgery from Pre-Surgery Profiles
This study tests whether pre-surgical patient traits can predict how quality of life changes after bariatric surgery for adults in the GEROM73 program.
-
Endoscopic treatment for overweight and mild obesity using Orbera365
This study is testing whether the Orbera365 intragastric balloon can help people who are overweight or mildly obese lose weight over a year.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.